CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Drug
Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the completion of 1,200 patient...
Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...
BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial
Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...
SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301
SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study
Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States...
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease...
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III...
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center,...
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical...
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1...